

IFW

TRANSMITTAL FORM <small>(to be used for all correspondence after initial filing)</small>		Application Number	10/769,574
		Filing Date	January 29, 2004
		First Named Inventor	Bret Berner
		Art Unit	1616
		Examiner Name	Edward J. Webman
Mail Stop	Amendment	Attorney Docket Number	3100-0001.10

ENCLOSURES (Check all that apply)

<input checked="" type="checkbox"/> No fee due <input type="checkbox"/> Fee(s) due: \$ _____ <input type="checkbox"/> Check enclosed <input type="checkbox"/> Charge Deposit Account No. 18-0580 <input type="checkbox"/> 37 CFR § 1.16 <input type="checkbox"/> 37 CFR § 1.17 <input checked="" type="checkbox"/> The Commission is authorized to charge any underpayment or credit any overpayment to Deposit Account No. 18-0580 <input checked="" type="checkbox"/> Return postcard <input type="checkbox"/> Amendment/Response <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) - _____ Affidavits/declaration(s) <input type="checkbox"/> _____-Month Extension of Time	<input type="checkbox"/> Terminal Disclaimer <input checked="" type="checkbox"/> Information Disclosure Statement & PTO-1449 Form(s) <input checked="" type="checkbox"/> Copies of cited reference (DS-DZ) <input type="checkbox"/> Response to Missing Parts / Incomplete Application <input type="checkbox"/> Declaration(s) by Inventor(s) <input type="checkbox"/> Preliminary Amendment <input type="checkbox"/> Updated Application Data Sheet <input type="checkbox"/> Drawing(s) - _____ Sheets <input type="checkbox"/> Compact Disk(s) - _____ CD(s) <input type="checkbox"/> Petition <input type="checkbox"/> Power of Attorney & Address Indication Form	<input type="checkbox"/> Revocation of & New Power of Attorney, Address Indication Form <input type="checkbox"/> Request for Refund <input type="checkbox"/> After Allowance Communication to a Technology Center (TC) <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to TC (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Other Enclosure(s) (see remarks): Claim Count <table border="1"> <tr> <td>Total Claims</td> <td>_____</td> <td>Extra Claims</td> <td>_____</td> <td>New Claim No.</td> </tr> <tr> <td>Independent Claims</td> <td>_____</td> <td>- 20 =</td> <td>_____</td> <td>_____</td> </tr> <tr> <td></td> <td>_____</td> <td>- 3 =</td> <td>_____</td> <td>_____</td> </tr> </table>	Total Claims	_____	Extra Claims	_____	New Claim No.	Independent Claims	_____	- 20 =	_____	_____		_____	- 3 =	_____	_____
Total Claims	_____	Extra Claims	_____	New Claim No.													
Independent Claims	_____	- 20 =	_____	_____													
	_____	- 3 =	_____	_____													

REMARKS

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT


Firm or Individual Name (print/type)	David A. Sadewasser, Reg. No. 55,587 Reed Intellectual Property Law Group	Telephone	(650) 251-7700
--------------------------------------	--	-----------	----------------

Signature	David Sadewasser	Date	November 30, 2005
-----------	------------------	------	-------------------

CERTIFICATE OF TRANSMISSION/MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below.

Name (print/type)	Joe Clark		
Signature		Date	November 30, 2005



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

INFORMATION Specification of:

Bret BERNER et al.

Serial No.: 10/769,574

Confirmation No.: 8962

Filing Date: January 29, 2004

Group Art Unit: 1616

Title: GASTRIC RETENTIVE ORAL DOSAGE FORM WITH RESTRICTED DRUG
RELEASE IN THE LOWER GASTROINTESTINAL TRACT

Examiner: Edward J. Webman

INFORMATION DISCLOSURE STATEMENT

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

This is a Supplemental Information Disclosure Statement submitted for the Examiner's consideration. Applicants respectfully request that the Examiner review and make of record the references identified below.

A PTO-1449 form listing the references accompanies this paper. Applicants would appreciate the Examiner's initialing and returning the form to indicate that the references have been reviewed and made of record. The references are as follows:

U.S. PATENT DOCUMENTS		
Document No.	Issue Date or Publication Date	Name of Patentee or Applicant
6,248,363	6/19/01	Patel et al.
6,562,375	5/13/03	Sako et al
2003/0091630 A1	5/15/03	Louie-Helm et al.
2003/0133985 A1	7/17/03	Louie-Helm et al.
2003/0152622 A1	8/14/03	Louie-Helm et al.
2004/0156899 A1	8/12/04	Louie-Helm et al.

NONPATENT DOCUMENTS

BLOEM et al., "A controlled trial of a slow-release form of furosemide in hypertension," Curr. Ther. Res. (1981) 29:577-583.

BOLES PONTO et al., "Furosemide (frusemide): a pharmacokinetic/pharmacodynamic review," (Parts I and II), Clin. Pharmacokinetics (1990) 18:381-471.

GABR et al., "Formulation and evaluation of buffered floating furosemide delivery systems," S.T.P. Pharma Sci. (2000) 10:181-186.

NONPATENT DOCUMENTS

IANNUCCELLI et al., "PVP solid dispersions for the controlled release of furosemide from a floating multiple-dose unit system," Drug Dev. Indus. Pharm. (2000) 26:595-603.
KANIWA et al., "The bioavailability of flufenamic acid and its dissolution rate from capsules," Intl. J. Clin. Pharmacol., Ther. Toxicol. (1983) 21:56-63.
MENON et al., "Development and evaluation of a monolithic floating dosage form for furosemide," J. Pharmac. Sci. (1994) 83:239-245.
UCHINO et al., "Clinical pharmacokinetics and diuretic effect of furosemide in plain tablet and retard capsule with normal subjects and cirrhotic patients," J. Pharm. Dyn. (1983) 6:684-691.
WAKELKAMP et al., "The influence of frusemide formulation on diuretic effect and efficiency," J. Clin. Pharmacol. (1999) 48:361-366.

This Information Disclosure Statement is not intended as a representation that a search has been made, that additional information material to the examination of this application does not exist, or that any of the above references constitutes prior art to the present application within the meaning of 35 USC § 102.

As applicants have not yet received a first Action on the merits, no fee is required for filing this Information Disclosure Statement. If, however, the PTO finds that for some reason a fee is found to be necessary, our Deposit Account No. 18-0580 may be charged therefor.

Respectfully submitted,

By: David Sadewasser
David A. Sadewasser
Registration No. 55,587

REED INTELLECTUAL PROPERTY LAW GROUP
1400 Page Mill Road
Palo Alto, California 94304
(650) 251-7700 Telephone
(650) 251-7739 Facsimile

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

1

of

1

Complete if Known

Application Number	10/769,574
Filing Date	January 29, 2004
First Named Inventor	Bret BERNER
Art Unit	1616
Examiner Name	Edward J. Webman
Attorney Docket Number	3100-0001.10

DEC 05 2003

TRADEMAILED

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No.	Document No.	Issue Date or Publication Date	Name of Patentee or Applicant of Cited Document	Class	Subclass	Filing Date if Appropriate
/A.H./	DM	6,248,363	6/19/01	Patel et al.			
	DN	6,562,375	5/13/03	Sako et al			
	DO	2003/0091630 A1	5/15/03	Louie-Helm et al.			
	DP	2003/0133985 A1	7/17/03	Louie-Helm et al.			
	DQ	2003/0152622 A1	8/14/03	Louie-Helm et al.			
/A.H./	DR	2004/0156899 A1	8/12/04	Louie-Helm et al.			

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.	Foreign Patent Document No.	Publication Date	Country	Class	Subclass	T

OTHER DOCUMENTS — NONPATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), Title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T
/A.H./	DS	BLOEM et al., "A controlled trial of a slow-release form of furosemide in hypertension," Curr. Ther. Res. (1981) 29:577-583.	
	DT	BOLES PONTO et al., "Furosemide (frusemide): a pharmacokinetic/pharmacodynamic review," (Parts I and II), Clin. Pharmacokinetics (1990) 18:381-471.	
	DU	GABR et al., "Formulation and evaluation of buffered floating furosemide delivery systems," S.T.P. Pharma Sci. (2000) 10:181-186.	
	DV	IANNUCCELLI et al., "PVP solid dispersions for the controlled release of furosemide from a floating multiple-dose unit system," Drug Dev. Indus. Pharm. (2000) 26:595-603.	
	DW	KANIWA et al., "The bioavailability of flufenamic acid and its dissolution rate from capsules," Intl. J. Clin. Pharmacol., Ther. Toxicol. (1983) 21:56-63.	
	DX	MENON et al., "Development and evaluation of a monolithic floating dosage form for furosemide," J. Pharmac. Sci. (1994) 83:239-245.	
	DY	UCHINO et al., "Clinical pharmacokinetics and diuretic effect of furosemide in plain tablet and retard capsule with normal subjects and cirrhotic patients," J. Pharm. Dyn. (1983) 6:684-691.	
/A.H./	DZ	WAKELKAMP et al., "The influence of frusemide formulation on diuretic effect and efficiency," J. Clin. Pharmacol. (1999) 48:361-366.	

Examiner Signature	/Andriae Holt/	Date Considered	04/09/2008
--------------------	----------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.